Asthma accounted for an 18.7% share of the global clinical trials within the Respiratory therapy area in 2021, registering a decrease of 4.1% when compared with the last ten-year average of 22.8% share, according to GlobalData .

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Asthma

Industry sponsored trials held a 61.8% share of all the clinical trials for Asthma indication in 2021, registering an increase of 7.3% when compared with the ten-year average of 54.5%. Non-industry sponsored trials accounted for a 38.2% share in 2021, marking a decrease of 7.3% over the ten-year average of 45.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Asthma trials

Asia-Pacific was the top region for industry sponsored Asthma trials, accounting for a 59.8% share in 2021, when compared with the five-year average of 50.4% and ten-year average of 41.7%.

Europe was at the second position with a 39.4% share in 2021, over the five-year average of 47.4% and ten-year average of 53.3%, followed by North America with an 18.2% share in 2021, as against five-year and ten-year averages of 24.7% and 31.5% respectively.

Middle East and Africa stood fourth with a 4.5% share in 2021, compared with the five-year average of 7.2% and ten-year average of 9.4%, followed by South and Central America with a 3.8% share in 2021, over five-year and ten-year averages of 9.2% and 11.3% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Asthma trials, accounting for a 39.4% share in 2021, as against the five-year average of 26.0% and ten-year average of 14.5%.

The US held a 14.4% share in 2021, over the five-year average of 22.8% and ten-year average of 28.5%, followed by the UK with a 12.1% share in 2021, compared with the five-year and ten-year averages of 14.3% and 18.3% respectively.

Canada held a 9.8% share in 2021, as against the five-year average of 9.3% and ten-year average of 11.4%.

Germany held a 9.8% share in 2021, over the five-year and ten-year averages of 19.3% and 21.0% respectively.

Top regions of non-industry sponsored Asthma trials

Asia-Pacific was the top region for non-industry sponsored Asthma trials, accounting for a 37.0% share in 2021 when compared with the five-year average of 46.6% and ten-year average of 43.6%.

Europe was at the second position with a 28.4% share in 2021, over the five-year and ten-year averages of 20.1% and 21.0% respectively, followed by North America with a 23.5% share in 2021, as against the five-year average of 17.7% and ten-year average of 20.0%.

The Middle East and Africa stood at the fourth position with a 9.9% share in 2021, compared with the five-year average of 13.9% and ten-year average of 13.6%, followed by South and Central America with a 1.2% share in 2021, over the five-year and ten-year averages of 2.0% and 2.1% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Asthma trials, accounting for a 17.3% share in 2021, as against the five-year average of 11.9% and ten-year average of 11.3%.

The US held a 16.0% share in 2021, over the five-year average of 14.0% and ten-year average of 15.6%, followed by Iran with an 8.6% share, compared with the five-year and ten-year averages of 12.3% and 11.1% respectively.

Canada held a 7.4% share in 2021, as against the five-year average of 3.8% and ten-year average of 4.1%.

The UK held a 6.2% share in 2021, over the five-year average of 6.1% and ten-year average of 5.9%.

Phase I trials lead industry sponsored clinical trials for Asthma in 2021

Phase I trials held a 53.7% share of industry sponsored clinical trials for Asthma in 2021, over the five-year average of 43.2% and ten-year average of 38.5%.

Phase III trials held an 18.4% share in 2021, as against the five-year average of 21.8% and ten-year average of 24.4%. Phase IV trials held a 14.3% share in 2021, compared with the five-year and ten-year averages of 15.4% and 12.5% respectively.

Phase II trials held a 13.6% share in 2021, over the five-year average of 19.6% and ten-year average of 24.6%.

Phase IV trials lead non-industry sponsored clinical trials for Asthma in 2021

Phase IV trials held a 36.3% share of non-industry sponsored clinical trials for Asthma in 2021, over the five-year average of 27.1% and ten-year average of 27.6%.

Phase II trials held a 26.4% share in 2021, as against the five-year average of 44.9% and ten-year average of 47.3%. Phase III trials held a 23.1% share, compared with the five-year and ten-year averages of 18.9% and 17.0% respectively.

Phase I trials held a 14.3% share in 2021, over the five-year average of 9.1% and ten-year average of 8.1%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.